Reviewing Lucid Diagnostics (NASDAQ:LUCD) and DIH Holding US (NASDAQ:DHAI)

DIH Holding US (NASDAQ:DHAI) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for DIH Holding US and Lucid Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DIH Holding US	0	0	0	0	0.00
Lucid Diagnostics	0	0	4	1	3.20

Lucid Diagnostics has a consensus target price of $3.69, indicating a potential upside of 269.12%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than DIH Holding US.

Institutional & Insider Ownership

27.8% of DIH Holding US shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 49.6% of DIH Holding US shares are held by company insiders. Comparatively, 8.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares DIH Holding US and Lucid Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DIH Holding US	N/A	-5.07%	3.35%
Lucid Diagnostics	-1,069.87%	N/A	-123.54%

Volatility & Risk

DIH Holding US has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Valuation and Earnings

This table compares DIH Holding US and Lucid Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DIH Holding US	$64.47 million	0.67	-$8.44 million	N/A	N/A
Lucid Diagnostics	$4.19 million	14.15	-$52.67 million	($1.14)	-0.88

DIH Holding US has higher revenue and earnings than Lucid Diagnostics.

Summary

Lucid Diagnostics beats DIH Holding US on 8 of the 13 factors compared between the two stocks.

About DIH Holding US

DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.